Targeting KLHL5 may offer an alternative method to modulate cell cycle activity, a popular anti-cancer strategy showing clinical potential in single treatment with inhibitors such as Barasertib [15–17] or with the ability to overcome drug resistance or treat refractory disease when used in combinatorial therapies [18–20]. This evidence concerns the gene KLHL5 and cancer.